Innate Pharma Past Earnings Performance

Past criteria checks 0/6

Innate Pharma's earnings have been declining at an average annual rate of -26.4%, while the Biotechs industry saw earnings growing at 7.7% annually. Revenues have been declining at an average rate of 16.7% per year.

Key information

-26.4%

Earnings growth rate

-26.3%

EPS growth rate

Biotechs Industry Growth-14.6%
Revenue growth rate-16.7%
Return on equity-118.3%
Net Margin-100.8%
Next Earnings Update27 Mar 2025

Recent past performance updates

Recent updates

Revenue & Expenses Breakdown

How Innate Pharma makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

DB:IDDA Revenue, expenses and earnings (EUR Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Jun 2434-34190
31 Mar 2448-21190
31 Dec 2362-8180
30 Sep 2357-35190
30 Jun 2352-63190
31 Mar 2355-60210
31 Dec 2258-58220
30 Sep 2257-40240
30 Jun 2257-22250
31 Mar 2241-34250
31 Dec 2125-45260
30 Jun 2146-8170
31 Mar 2158-4180
31 Dec 2070-1190
30 Sep 2067-54310
30 Jun 2063-44310
31 Mar 2075-33280
31 Dec 19858210
30 Sep 191085240
30 Jun 1913031220
31 Mar 1911217200
31 Dec 18943180
30 Sep 1870-19160
30 Jun 1846-40150
31 Mar 1845-44160
31 Dec 1744-48170
30 Sep 1755-28160
30 Jun 1766-8140
31 Mar 17663120
31 Dec 166613100
30 Sep 1653580
30 Jun 1641-270
31 Mar 1633-460
31 Dec 1525-760
30 Sep 1517-1350
30 Jun 158-1940
31 Mar 158-1940
31 Dec 148-2050
30 Sep 1411-1560
30 Jun 1414-1080
31 Mar 1415-680
31 Dec 1317-380

Quality Earnings: IDDA is currently unprofitable.

Growing Profit Margin: IDDA is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: IDDA is unprofitable, and losses have increased over the past 5 years at a rate of 26.4% per year.

Accelerating Growth: Unable to compare IDDA's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: IDDA is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-18.2%).


Return on Equity

High ROE: IDDA has a negative Return on Equity (-118.25%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/25 03:01
End of Day Share Price 2024/12/23 00:00
Earnings2024/06/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Innate Pharma S.A. is covered by 15 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Olga SmolentsevaBryan Garnier & Co
Yigal NochomovitzCitigroup Inc
Michael Thomas CooperEdison Investment Research